KJ Smith, MS Roberts - Annals of internal medicine, 2001 - Am Coll Physicians The Editors welcome submissions for possible publication in the Letters section.
Authors of letters should: • Include no more than 300 words of text, three
authors, and five references • Type with double-spacing • Send three ... Cited by 44 - Related articles - All 6 versions
EA Stolk, JJV Busschbach, M Caffa, EJH … - British Medical Journal, 2000 - bmj.com You are seeing this message because your web browser does not support basic web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Elly A Stolk , research ... Cited by 51 - Related articles - BL Direct - All 13 versions
MR McGarvey - Annals of internal medicine, 2000 - ncbi.nlm.nih.gov 1: Ann Intern Med. 2000 Jun 20;132(12):994-5. Comment on: Ann Intern Med. 2000 Jun
20;132(12):933-7. Tough choices: the cost-effectiveness of sildenafil. ... Cited by 8 - Related articles - All 2 versions
- ►adisonline.com [PDF] JM Plumb, JF Guest - Pharmacoeconomics, 1999 - ingentaconnect.com Jonathan M Plumb and Julian F Guest ... Catalyst Health Economics Consultants
Ltd, Pinner, Middlesex, England ... Abstract Objective: The objective of this
study was to estimate the annual socioeconomic burden imposed by erectile ... Cited by 17 - Related articles - All 5 versions
AM Fendrick - The American journal of managed care, 2000 - ncbi.nlm.nih.gov While effective therapies exist for health conditions that diminish the quality
of life, there remain hurdles in healthcare delivery that may limit access to
such therapies for individuals who would benefit from them. Limited company ... Cited by 5 - Related articles
AG Anastasiadis, MA Ghafar, R Shabsigh, M … - eop, 2002 - informahealthcare.com The introduction of safe and effective oral therapies has changed the signifi-
cance of erectile dysfunction (ED) forever. Seldom has a new drug changed the
landscape of pharmacotherapy in so many ways as sildenafil (Viagra™, ... Cited by 6 - Related articles - All 5 versions
YS Kwok, C Kim - Effective clinical practice: ECP - ncbi.nlm.nih.gov CONTEXT: The use of Viagra (sildenafil) (Pfizer, New York, New York) for
treating impotence has increased dramatically. However, the cost of the drug and
philosophical questions about what defines a medical condition have sparked ... Cited by 6 - Related articles - BL Direct
R Shabsigh - Urologic Clinics of North America, 2001 - Elsevier With the introduction of successful oral therapy with sildenafil (Viagra), the
socioeconomics of erectile dysfunction have been changed forever. The erectile
dysfunction population has expanded significantly and rapidly with more ... Cited by 11 - Related articles - BL Direct - All 12 versions
- ►adisonline.com [PDF] ECF Wilson, ES McKeen, PA Scuffham, MCJ … - Pharmacoeconomics, 2002 - ingentaconnect.com Edward CF Wilson, 1 Emma S. McKeen, 2 Paul A. Scuffham, 1 Martin CJ Brown, 3 ... Kevan Wylie 4 and Geoff Hackett 5 ... 1 York Health Economics Consortium
Ltd, University of York, York, UK 2 Pfizer Limited, Walton Oaks, Surrey, UK ... Cited by 17 - Related articles - BL Direct - All 9 versions
